Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma
Identifieur interne : 000182 ( Main/Exploration ); précédent : 000181; suivant : 000183Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma
Auteurs : RBID : ISTEX:259_1994_Article_BF02426696.pdfEnglish descriptors
- KwdEn :
Abstract
In a prospective study we examined 38 patients with primary bronchogenic carcinoma to validate the use of indium- I 11 pentetreotide (IPT) as a diagnostic tool. Of these 38 patients, 25 had small cell lung cancer (SCLC) and 13, non-small cell lung cancer (NSCLC). The aim of the study was to investigate whether (a) the disease can be reliably detected, (b) IPT allows differentiation between SCLC and NSCLC and (c) IPT provides further information on metastatic disease. After giving their informed consent the patients were injected and imaged 4 and 24 h later using a planar whole-body technique. In addition single-photon emission tomography of the thorax and, if necessary, other areas of the body was performed at 24 h. In the 25 patients with SCLC 22 sites of primary tumour were correctly identified (true-positive, TP); one was false-negative (FN) and two were true-negative (TN), the patients being in full remission. Metastases were correctly identified in ten instances (lung,bone and brain), while the findings were FN in five cases. An additional six FN findings resulted in the area of the upper abdomen due to the physiological uptake in the liver, spleen and kidneys. In the 13 patients with NSCLC, ten findings were TP and 3 FN with respect to the primary tumour. Two FNs were squamous cell carcinoma, and one, adenocarcinoma. Metastases were TP in nine cases and FN in one. We therefore conclude: (1) IPT is a highly sensitive method for the detection of primary bronchogenic carcinoma, and in particular for SCLC, (2) differentiation between SCLC and NSCLC cannot be achieved and (3) the method is of limited use in the search for metastatic disease. Compared with the conventional imaging modalities like X-ray, CT and bone scintigraphy, IPT provides only a small amount of additional diagnostic information.
DOI: 10.1007/BF02426696
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma</title><author><name>Carl-Martin Kirsch</name><affiliation wicri:level="3"><mods:affiliation>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name>Joachim von Pawel</name><affiliation wicri:level="1"><mods:affiliation>Division of Oncology, Gauting, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Division of Oncology, Gauting</wicri:regionArea><wicri:noRegion>Gauting</wicri:noRegion><wicri:noRegion>Gauting</wicri:noRegion></affiliation></author><author><name>Irene Grau</name><affiliation wicri:level="3"><mods:affiliation>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name>Klaus Tatsch</name><affiliation wicri:level="3"><mods:affiliation>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1994_Article_BF02426696.pdf</idno><date when="1994">1994</date><idno type="doi">10.1007/BF02426696</idno><idno type="wicri:Area/Main/Corpus">000058</idno><idno type="wicri:Area/Main/Curation">000058</idno><idno type="wicri:Area/Main/Exploration">000182</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bronchogenic carcinoma</term><term>Indium-111 pentetreotide</term><term>Radionuclide imaging</term><term>Somatostatin receptors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">In a prospective study we examined 38 patients with primary bronchogenic carcinoma to validate the use of indium- I 11 pentetreotide (IPT) as a diagnostic tool. Of these 38 patients, 25 had small cell lung cancer (SCLC) and 13, non-small cell lung cancer (NSCLC). The aim of the study was to investigate whether (a) the disease can be reliably detected, (b) IPT allows differentiation between SCLC and NSCLC and (c) IPT provides further information on metastatic disease. After giving their informed consent the patients were injected and imaged 4 and 24 h later using a planar whole-body technique. In addition single-photon emission tomography of the thorax and, if necessary, other areas of the body was performed at 24 h. In the 25 patients with SCLC 22 sites of primary tumour were correctly identified (true-positive, TP); one was false-negative (FN) and two were true-negative (TN), the patients being in full remission. Metastases were correctly identified in ten instances (lung,bone and brain), while the findings were FN in five cases. An additional six FN findings resulted in the area of the upper abdomen due to the physiological uptake in the liver, spleen and kidneys. In the 13 patients with NSCLC, ten findings were TP and 3 FN with respect to the primary tumour. Two FNs were squamous cell carcinoma, and one, adenocarcinoma. Metastases were TP in nine cases and FN in one. We therefore conclude: (1) IPT is a highly sensitive method for the detection of primary bronchogenic carcinoma, and in particular for SCLC, (2) differentiation between SCLC and NSCLC cannot be achieved and (3) the method is of limited use in the search for metastatic disease. Compared with the conventional imaging modalities like X-ray, CT and bone scintigraphy, IPT provides only a small amount of additional diagnostic information.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="0b826f307a48ddd7fabd24a458b507c94fdd9cf6"><titleInfo lang="eng"><title>Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma</title></titleInfo><name type="personal"><namePart type="given">Carl-Martin</namePart><namePart type="family">Kirsch</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München, Germany</affiliation></name><name type="personal"><namePart type="given">Joachim</namePart><namePart type="family">von Pawel</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Division of Oncology, Gauting, Germany</affiliation></name><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Grau</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München, Germany</affiliation></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Tatsch</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Nuklearmedizinische Klinik, Klinikum Großhadern, D-81366, München, Germany</affiliation></name><typeOfResource>text</typeOfResource><genre>Original article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1994-01-06</dateCreated><dateValid encoding="w3cdtf">2006-05-05</dateValid><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">In a prospective study we examined 38 patients with primary bronchogenic carcinoma to validate the use of indium- I 11 pentetreotide (IPT) as a diagnostic tool. Of these 38 patients, 25 had small cell lung cancer (SCLC) and 13, non-small cell lung cancer (NSCLC). The aim of the study was to investigate whether (a) the disease can be reliably detected, (b) IPT allows differentiation between SCLC and NSCLC and (c) IPT provides further information on metastatic disease. After giving their informed consent the patients were injected and imaged 4 and 24 h later using a planar whole-body technique. In addition single-photon emission tomography of the thorax and, if necessary, other areas of the body was performed at 24 h. In the 25 patients with SCLC 22 sites of primary tumour were correctly identified (true-positive, TP); one was false-negative (FN) and two were true-negative (TN), the patients being in full remission. Metastases were correctly identified in ten instances (lung,bone and brain), while the findings were FN in five cases. An additional six FN findings resulted in the area of the upper abdomen due to the physiological uptake in the liver, spleen and kidneys. In the 13 patients with NSCLC, ten findings were TP and 3 FN with respect to the primary tumour. Two FNs were squamous cell carcinoma, and one, adenocarcinoma. Metastases were TP in nine cases and FN in one. We therefore conclude: (1) IPT is a highly sensitive method for the detection of primary bronchogenic carcinoma, and in particular for SCLC, (2) differentiation between SCLC and NSCLC cannot be achieved and (3) the method is of limited use in the search for metastatic disease. Compared with the conventional imaging modalities like X-ray, CT and bone scintigraphy, IPT provides only a small amount of additional diagnostic information.</abstract><subject lang="eng"><genre>Key words</genre><topic>Bronchogenic carcinoma</topic><topic>Somatostatin receptors</topic><topic>Radionuclide imaging</topic><topic>Indium-111 pentetreotide</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1994</partNumber><partNumber>Volume: 21</partNumber><partNumber>Number: 12</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1994-12-01</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic><topic>Cardiology</topic><topic>Oncology</topic><topic>Orthopedics</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 19</identifier><recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF02426696</identifier><identifier type="matrixNumber">Art9</identifier><identifier type="local">BF02426696</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>1318</start><end>1325</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin><recordIdentifier>259_1994_Article_BF02426696.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000182 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000182 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1994_Article_BF02426696.pdf
|texte= Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma
}}
| This area was generated with Dilib version V0.5.81. |  |